DESTINY-Breast03 Phase 3 Study Results
TDD in PRO Measures of Interest
Median (95% CI) TDD, months
DESTINY-Breast03
Daiichi-Sankyo
T-DXd
(n = 261)
EORTC
QLQ-C30
Global health status/QoLa
Pain symptomsb
9.7 (7.3-12.5)
10.8 (8.3-14.0)
T-DM1
(n = 263)
8.3 (7.0-10.3)
HR (95% CI)
Nominal
P value
0.88 (0.70-1.11)
0.2829
Physical functioningb
16.7 (14.5-NE)
8.3 (6.6-9.8)
10.3 (8.3-21.0)
0.75 (0.59-0.95)
0.0146
0.77 (0.59-1.01)
0.0529
Emotional functioningb
16.4 (14.1-19.9)
10.5 (9.0-13.8)
0.69 (0.53-0.89)
0.0049
Social functioningb
11.1 (7.3-13.4)
9.0 (7.1-11.3)
0.90 (0.71-1.14)
0.3577
Arm symptomsb
11.1 (8.5-14.8)
EORTC
QLQ-BR45
Breast symptomsb
EQ-5D-5L
VASb
26.4 (26.4-NE)
13.2 (10.1-15.3)
7.0 (5.6-9.3)
NE (NE-NE)
8.5 (7.3-10.4)
0.70 (0.55-0.89)
0.0033
0.76 (0.53-1.09)
0.1329
0.77 (0.61-0.98)
0.0354
0.5
1.0
1.5
2.0
Favors T-DXd
(log10)
Favors T-DM1
EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-5L, EuroQol 5-dimension, 5-level questionnaire; GHS, global health status; HR, hazard ratio;
PRO, patient-reported outcome; QLQ-BR45, Quality of Life Breast cancer questionnaire; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; TDD, time to
definitive deterioration; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan; VAS, visual analog scale.
P values are not adjusted for multiple testing. TDD is defined as a >10-point change from baseline. aPrimary PRO variable of interest. Secondary PRO variable of interest.
ESMO BC 2022 #1630 Oral
44View entire presentation